Prevalence and treatment of Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis in patients with non-gonococcal urethritis.
The aim of present study was to evaluate the occurrence of Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum in non-gonococcal urethritis (NGU) and to determine the bacterial resistance to six antibiotics in order to determine the most suitable treatment strategy. A total of 50 patients were enrolled into the study. Urethral samples were taken with a dacron swab placed into urethra 2 - 3 cm in males, and vaginal samples were taken from the endocervical region in women. The patient samples that did not grow Neisseria gonorrhoeae were accepted as NGU. Direct immunofluorescence technique was used for the investigation of C. trachomatis. Mycoplasma IST was used for the isolation of M. hominis and U. urealyticum. U. urealyticum was isolated from 24 patients. Thirteen of them had only U. urealyticum, and the rest had mixed pathogen organisms (7 U. urealyticum + M. hominis; 3 U. urealyticum + C. trachomatis, and 1 U. urealyticum + M. hominis + C. trachomatis). C. trachomatis was detected in 12 patients. While 8 patients had C. trachomatis only, the rest had a mixture of the pathogen organisms listed above. Partner examinations could be performed for only 22 patients' partners. In the evaluation of antibiotic susceptibility, higher resistance was obtained against ofloxacin in U. urealyticum, and against erythromycin with M. hominis. Our results indicated that doxycycline or ofloxacin should be the first choice when empirical treatment is necessary.
Kilic
Dilek
D
Department of Infectious Diseases and Clinical Microbiology, University of Kirikkale Faculty of Medicine, Kirikkale, Turkey. mmbasar@hotmail.com
Basar
M Murada
MM
Kaygusuz
Sedat
S
Yilmaz
Erdal
E
Basar
Halil
H
Batislam
Ertan
E
D000328:Adult; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000188:drug therapy / Q000453:epidemiology*; D002692:Chlamydia trachomatis / Q000187:drug effects / Q000302:isolation & purification*; D004318:Doxycycline / Q000494:pharmacology / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D009175:Mycoplasma Infections / Q000188:drug therapy / Q000453:epidemiology*; D019535:Mycoplasma hominis / Q000187:drug effects / Q000302:isolation & purification*; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D015995:Prevalence; D016896:Treatment Outcome; D016869:Ureaplasma Infections / Q000188:drug therapy / Q000453:epidemiology*; D016990:Ureaplasma urealyticum / Q000187:drug effects / Q000302:isolation & purification*; D014521:Urethra / Q000382:microbiology; D014526:Urethritis / Q000188:drug therapy / Q000382:microbiology*
D000892:Anti-Infective Agents, Urinary; D004917:Erythromycin; D015242:Ofloxacin; D004318:Doxycycline